Axsome Therapeutics Inc annual gross profit for fiscal TTM was $724 million, an increase of 22.5% from $591 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $724M | $591M | $352M | $245M | $45M | ($1M) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $205M | $176M | $184M | $159M | $137M | $112M | $108M | $96M | $79M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More AXSM metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All AXSM financial statements → Interactive AXSM charts →
About TickerBase · Data methodology & sources · Privacy · Terms